The presented invention relates to a process for preparation of Enzalutamide, compound (1) or a salt or a solvate thereof Formula (1). The presented invention also related to 1,4-dioxane solvate of compound (1).

##STR00001##

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

This disclosure relates to medicines, and more particularly to a platelet aggregation inhibitor, a pharmaceutical composition containing the same and a preparation and application thereof. The platelet aggregation inhibitor provided herein is a compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer or a pharmaceutically-acceptable solvate thereof. This application also provides an application of the compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer, a pharmaceutically-acceptable solvate or a pharmaceutical composition thereof in the treatment of thrombus.

A compound (A) is represented by the formula (1):

##STR00001## wherein R.sup.1 is a hydrogen atom or an alkali metal atom, R.sup.2 is a hydrogen atom or an alkali metal atom, R.sup.3 is a hydrogen atom or a methyl group, Z is a divalent or trivalent organic group, and the lines consisting of a solid line and a broken line bonded to Z represent a single bond or a double bond.

A compound (A) is represented by the formula (1):

##STR00001## wherein R.sup.1 is a hydrogen atom or an alkali metal atom, R.sup.2 is a hydrogen atom or an alkali metal atom, R.sup.3 is a hydrogen atom or a methyl group, Z is a divalent or trivalent organic group, and the lines consisting of a solid line and a broken line bonded to Z represent a single bond or a double bond.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.